Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Study Objective. To analyze the disproportionality of reporting of hyperprolactinemia, galactorrhea, and pituitary tumors with seven widely used antipsychotic drugs. Design. Retrospective pharmacovigilance study. Data Source. United States Food and Drug Administration's Adverse Event Reporting System (AERS) database. Intervention. We initially identified higher‐than‐expected postmarketing reports of pituitary tumors associated with risperidone, a potent dopamine D 2‐receptor antagonist antipsychotic, by analyzing reporting patterns of these tumors in the AERS database. To further examine this association, we analyzed disproportionate reporting patterns of pituitary tumor reports for seven antipsychotics with different affinities for blocking D 2 receptors: aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and haloperidol. Measurements and Main Results. To conduct both of these analyses, we used the Multi‐item Gamma Poisson Shrinker (MGPS) data mining algorithm applied to the AERS database. The MGPS uses a Bayesian model to calculate adjusted observed:expected ratios of drug–adverse event associations (Empiric Bayes Geometric Mean [EBGM] values) in huge drug safety databases. The higher the adjusted reporting ratio, or EBGM value, the greater the strength of the association between a drug and an adverse event. Risperidone had the highest adjusted reporting ratios for hyperprolactinemia (EBGM 34.9, 90% confidence interval [CI] 32.8–37.1]), galactorrhea (EBGM 19.9, 90% CI 18.6–21.4), and pituitary tumor (EBGM 18.7, 90% CI 14.9–23.3) among the seven antipsychotics, and one of the highest scores for all drugs in the AERS database. Some tumors were associated with visual field defects, hemorrhage, convulsions, surgery, and severe (> 10‐fold) prolactin elevations. The EBGM values for risperidone for these adverse events were higher in women, but high EBGM values for these events were also seen in men and children. Moreover, the rank order of the EBGM values for pituitary tumors corresponded to the affinities of these seven drugs for D 2 receptors. Conclusion. Treatment with potent D 2‐receptor antagonists, such as risperidone, may be associated with pituitary tumors. These findings are consistent with animal (mice) studies and raise the need for clinical awareness and longitudinal studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
KRISHNAN, K. R. R., DORAISWAMY, P. M., LURIE, S. N., FIGIEL, G. S., HUSAIN, M. M., BOYKO, O. B., ELLINWOOD, E. H., & NEMEROFF, C. B. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-256 · Cited by 232 · cited 1×
“To our knowledge, ours is the first systematic study of spontaneous adverse event data reported to the FDA to document an association between specific antipsychotic drugs and pituitary tumors in humans, although this association was suspected in case reports from more than 20 years ago.(29) There are other causes of p…”
BackgroundSelf-citationAnterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter
Bossé, R., Fumagalli, F., Jaber, M., Giros, B., Gainetdinov, R. R., Wetsel, W. C., Missale, C., & Caron, M. G. (1997) · Neuron · doi:10.1016/s0896-6273(00)80353-0 · Cited by 203 · cited 2×
“In these mice, prolactin levels are 6 times higher in female mice, and female mice develop tumors much earlier than male mice.(12) Long-term treatment of wild-type mice with many antipsychotics can promote pituitary adenomas or adenocarcinomas.”
BackgroundDopamine Antagonists and the Development of Breast Cancer
Wang, P. S., Walker, A. M., Tsuang, M. T., Orav, E. J., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1147 · Cited by 196 · cited 1×
“The long-term consequences of antipsychoticassociated hyperprolactinemia in humans are not well studied.(10) Prolactin secretion from anterior pituitary lactotroph cells is under inhibitory control by dopamine, and blockade of dopamine D2 receptors by antipsychotic drugs stimulates lactotroph proliferation and prolact…”
Background
Cited by
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“Although a pharmacovigilance study raised concern about a possible association between prolactin-raising antipsychotics and prolactinomas (201), evidence for a causal relationship is missing (Table 2).”
BackgroundBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224
Byerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815ac4e5 · Cited by 153
Pituitary volume in psychosis: the first review of the evidence
Pariante, C. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107084020 · Cited by 73
“Moreover, the stimulating effects of prolactin-inducing antipsychotics on lactotrophs could partially explain the recent preliminary evidence suggesting an increased risk of developing pituitary tumours in subjects taking prolactin-elevating antipsychotics (Szarfman et al., 2006).”
BackgroundPituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder
Mondelli, V., Dazzan, P., Gabilondo, A., Tournikioti, K., Walshe, M., Marshall, N., Schulze, K. K., Murray, R. M., McDonald, C., & Pariante, C. M. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.05.010 · Cited by 72
“Our findings demonstrate that these effects have long-lasting macroscopic consequences on the pituitary, and this is of particular clinical relevance as could contribute to the increased risk of developing pituitary tumours in subjects taking these drugs (Szarfman et al., 2006).”
Background
Metadata
- Authors
- Szarfman, A., Tonning, J. M., Levine, J. G., & Doraiswamy, P. M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 26
- Issue
- 6
- Pages
- 748-758
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2156455388
- Cited by
- 145
- References
- 5
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.